Inogen (NASDAQ:INGN) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research note published on Friday.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Stock Performance

Shares of INGN opened at $8.48 on Friday. Inogen has a fifty-two week low of $5.08 and a fifty-two week high of $13.33. The firm has a 50-day simple moving average of $9.46 and a 200-day simple moving average of $9.74. The company has a market capitalization of $201.98 million, a price-to-earnings ratio of -3.77 and a beta of 1.02.

Hedge Funds Weigh In On Inogen

Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. purchased a new stake in shares of Inogen in the second quarter valued at about $30,000. Quarry LP purchased a new stake in Inogen in the 3rd quarter valued at approximately $59,000. Verition Fund Management LLC purchased a new stake in Inogen in the 3rd quarter valued at approximately $106,000. Virtu Financial LLC acquired a new position in Inogen during the 3rd quarter worth approximately $111,000. Finally, Paloma Partners Management Co purchased a new position in shares of Inogen during the 3rd quarter worth approximately $126,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.